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Since its introduction in 1998 [1], combined PET/CT has
gained clinical acceptance as an oncology imaging modal-
ity providing superior accuracy in tumour staging and
assessment of oncology therapy response compared to PET
or CT alone [2, 3] and to both imaging modalities viewed
side-by-side [4, 5]. The PET technology available in
combined PET/CT has advanced significantly over the
years and now supports emission imaging of the torso from
head to mid-thigh with isotropic sub-centimetre resolution
in 10 min, or less. The integration of high-end multidetector
CT in dual modality tomographs marks a trend towards
performing contrast-enhanced diagnostic CT studies, which
has progressively increased the clinical relevance of
integrated PET/CT imaging protocols. Undisputedly, these
changes in diagnostic pathways require the close collabo-
ration and even cross-specialist training of nuclear medicine
specialists and radiologists.
With the concurrent evolution of MR imaging technol-
ogies and sequences, MR studies can provide a wealth of
diagnostic information regarding soft-tissue analysis, tu-
mour detection, tissue characterization and functional
imaging. It is not uncommon today for patients to undergo
an MR study in addition to a PET/CT study as part of their
clinical workup for detection and staging of cancers if soft-
tissue characterization and morphological information that
CT alone cannot provide are required. It is, therefore, quite
rational to anticipate that combined PET/MR examinations
will potentially become more valuable than PET/CT
imaging followed by a complementary MR examination
[6] in PET indications where MR outperforms CT. It has
even been suggested that whole-body MR imaging
(WBMRI) could replace PET/CT [7]. However, such these
types of enthusiastic reports on the excellent diagnostic
performance of stand-alone MR imaging are based mostly
on using diffusion weighted (DW) sequences that show
particularly high sensitivity at the cost of low specificity,
and, therefore, may be of limited value in a cost-conscious
health-care system.
Technical innovation in combined PET/MR
The idea of combining PET and MR arose around the
same time that PET/CT was conceptualized. In the early
1990s Simon Cherry and Paul Marsden saw a need for
PET/MR in small-animal imaging studies to combine
high soft-tissue contrast with molecular information
provided by PET [8, 9]. PET/MR was destined to remain
in the preclinical arena for another decade until, in 2006,
the first simultaneous MR and PET images of the human
brain were acquired [10]. A major challenge for bringing
PET and MR technologies physically together is the
interferences between the high-field magnets and the
electronics of the PET scintillation detectors [11]. One
solution for PET detectors to be compatible with MR, is to
replace photomultipliers with avalanche photodiodes
(APD) that are less sensitive to magnetic fields, or to use
alternative solid-state technologies, which have been
proposed in prototype animal PET systems [12]. It is
O. Ratib (*)
Department of Medical Imaging and Information Sciences,







Eur J Nucl Med Mol Imaging (2011) 38:992–995
DOI 10.1007/s00259-011-1790-4
worth noting that, unlike combined PET/CT, dual modal-
ity PET/MR started out in the preclinical arena before
being adopted clinically, much supported by industry.
Today three concepts for human PET/MR systems are
vividly and often controversially discussed: separate PET,
or PET/CT and MR gantries operated in different rooms
(A), PET and MR gantries arranged in the direction of the
main scanner axis with a patient handling system mounted
in between (B), and a fully integrated PET/MR system
with simultaneous acquisition (C).
The integrated design (C), first presented in 2006, and
also the most challenging, is based on a PET detector ring
designed as an insert that can be placed inside a 3-T MR
scanner (Siemens Healthcare). This prototype system
(BrainPET) was anticipated for brain imaging only [10].
The PET insert has an internal diameter of 35.5 cm and
comprises LSO (lutetium oxyorthosilicate) detector blocks
made of 2.5-mm crystals coupled to an array of APDs that
have been shown to be operational in magnetic fields of up
to 7 T [8]. Four such units are now in research operation at
the University of Tübingen, Forschungszentrum Jülich,
MGH Boston and Emory University Atlanta.
The coplanar PET/MR concept (B), first presented in
2010, is based on a tandem design of a whole-body time-of-
flight (TOF) PET system and a 3-T MR system (Philips
Healthcare) with a rotating table platform in between.
Through minor modifications of the PET detector system
(e.g. orientation of the photomultiplier tube, minor shield-
ing) the PET gantry can be operated in close proximity to
the 3-T MR system. Two such whole-body units have been
installed and tested in clinical routine in Mount Sinai
Hospital in New York and at the University Hospital of
Geneva, and have been certified since January 2011 for
routine clinical use.
Design (A) was proposed by GE Healthcare in late
2010. It is available only as prototype technology and
has been installed and tested at the University Hospital
of Zurich. This design is based on a combination of a
dual modality PET/CT and a 3-T MR system that are
operated side-by-side in separate adjacent rooms; patients
are shuttled from one system to the other without getting
off the bed.
In an extension to the integrated design concept (C), a
similar system was proposed in late 2010 that merges a
whole-body PET with a 3-T MR system to allow
simultaneous torso and whole-body imaging. Just like the
BrainPET PET/MR prototype, this system is based on
LSO-APD PET detector technology that is integrated into
the MR gradient coil system offering a 60-cm gantry
opening (versus a 35-cm gantry opening for the brain
prototype). Since December 2010 two prototypes have been
installed in clinical settings at the Technical University of
Munich and the University of Tübingen.
PET/MR or PET/CT?
Since the introduction of PET/CT into clinical practice in
1998, clinical evidence for the diagnostic superiority of
PET/CT over CT and PET acquired separately has been
growing. This pertains to a number of indications, primarily
in oncology [13–15]. It is conceivable that similar advan-
tages over stand-alone imaging could be expected from
combining PET with high-resolution MR images. However,
the acquisition of whole-body MR data with adequate
anatomical resolution and within a reasonable total exam-
ination time, matching that of a whole-body PET/CT study
remains a challenge. As such, the existence of PET/CT may
be the biggest challenge to the concept of PET/MR, both in
terms of the diagnostic accuracy and logistical benefits.
Nonetheless, in several instances the information pro-
vided by MR cannot be obtained by CT [16]. For example,
MR is advantageous in soft-tissue characterization, such as
in parenchymal organs, the brain and bone lesions.
Therefore, the concept of combining PET and MR
continues to be of interest and clinical attention will
increase in particular as a combination of whole-body MR
techniques with specific tracer imaging in PET may provide
incremental diagnostic accuracy. In addition, further clini-
cally relevant information can be gathered by MR within
the same examination procedure. For example, advanced
MR imaging techniques can provide functional informa-
tion, for example MR spectroscopy (MRS), diffusion-
weighted and perfusion imaging, and functional MR
imaging (fMRI). As an example, MR breast imaging has
a high sensitivity in the detection of breast lesions but a
relatively low specificity [17]. In comparison, [18F]FDG
PET/CT imaging has gained a significant role in the
detection and staging of breast cancer patients with a
higher specificity than MR mammography [18, 19]. Fusion
of MR and PET data should, therefore, combine the high
sensitivity of MR imaging for detection of breast lesions
and the high specificity of PET for differentiating a benign
from a malignant lesion [6]. Other domains for combined
PET/MR are likely to be prostate cancer and head/neck
cancer imaging. Finally, replacing the CT in PET/CT with
MR could significantly reduce the effective patient expo-
sure, although this may be less relevant in oncology and in
elderly patients given their reduced life expectancy. It is,
however, beneficial in younger patients with potentially
curable disease and in patients with non-oncological
indications.
Despite the promising potential of dual modality PET/
MR, a number of methodological and clinical concerns
await resolution before PET/MR can become more widely
adopted in clinical routine. First, this relates to the
derivation of attenuation correction (AC) factors from
PET/MR data. Several techniques for calculation MR AC
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based on MR image segmentation of different tissue
characteristics of the body have been implemented and
tested [20], but numerous technical challenges for accurate
AC remain, including compensation for MR image trunca-
tion and correction for RF coils and accessories. Second,
PET/MR imaging protocols have a direct impact on patient
throughput. Adding emission acquisition time and multi-
sequence clinical MR imaging time could result in total
examination times that are significantly longer than those of
a comparable PET/CT study. Therefore, the combination of
PET and MR in a single imaging modality requires
modified imaging protocols that yield competitive exami-
nation times. Otherwise, two already long examination
times will add up to an examination time not acceptable in
clinical routine. While advanced MR imaging sequences
can provide relevant diagnostic information, they cannot be
applied to whole-body imaging. Specific imaging sequen-
ces may have to be restricted to organs and body sections
that benefit most from such imaging protocols, such as
body regions with an abnormal metabolic pattern as seen on
PET. Conversely, with higher efficiency PET systems using
TOF technology, imaging time can be reduced essentially
by half while maintaining equivalent or better image quality
than non-TOF PET systems. This should allow shorter PET
imaging times that leave more flexibility for additional
complementary MR sequences to be performed. Recently it
has been suggested that TOF can also be helpful in
reducing the effects of inconsistent data, such as erroneous
normalization, poor scatter estimates and mismatched or
inaccurate attenuation maps [21].
Most clinical protocols today require between two and
five additional MR series with dedicated protocols on
specific organs or body sections. These additional sequen-
ces can also be completed in under 30 minutes, allowing a
diagnostic PET/MR scan to be completed within an hour.
While such a study is longer than a standard diagnostic
PET/CT study, it is still shorter than the total time that a
PET/CT and an MRI study would take today if performed
on two separate systems at different times. This clearly
benefits patients who need both PET/CT and MR studies in
their clinical workup. We also believe that using the results
of the PET study to identify areas where additional MR
sequences must be applied could significantly reduce the
time for a diagnostic MR scan by limiting the number and
extent of these additional MR sequences by applying them
only to limited areas where suspicious PET uptake is
identified. Other challenges for the routine use of PET/MR
include methodological aspects, such as the fact that CT is
the modality of choice for the characterization of lung
lesions. In some patients with metal implants and pace-
makers, MR imaging may not be employed at all. Also, the
number of patients unable to undergo the study due to
claustrophobia is higher with MR than with CT.
Overall, we believe that in oncology applications MR
images can bring additional relevant diagnostic information
to PET images and the combination of the two modalities
can offer more accurate and specific diagnostic perfor-
mance than PET/CT alone [6]. Coregistered anatomy and
metabolic images should enable better staging and more
accurate lesion identification in a variety of tumour entities
such as liver and bone metastases, brain tumours, and
prostate, gynaecological, breast and head and neck cancers.
In thoracic tumours, however, PET/CT will still be
preferred. However, the added diagnostic value provided
by MR over CT and PET must be proven to be valuable and
valuable in the context of a presumably longer imaging
time if PET/MR is performed instead of PET/CT.
In follow-up studies of patients undergoing specific
oncological treatment, PET/MRI could become the modal-
ity of choice offering a more accurate and quantitative
assessment of patient tumour response to treatment. Special
protocols focused on specific body regions could use much
shorter MR sequences than those used for diagnostic
purposes. Repeated PET/MRI studies as part of patient
treatment monitoring would have the major advantage of
much lower radiation exposure than conventional PET/CT
used in most cases today. With the emergence of new
tracers, it is also expected that more specific and accurate
PET protocols will emerge for diagnosis and follow-up of
cancer, and also for prediction and assessment of patient
response to treatments [22]. The combination of PET and
MR images may be ideal for anatomical and metabolic
assessment of protocols and clinical pathways for oncology
[8].
While hybrid PET/MR may certainly not replace PET/
CT in all cases, it has the potential to improve workflow
and diagnostic accuracy in patients who already require
both a PET/CT and an MR examination as part of their
clinical workup.
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